Evidence map›Paper›PMID 27708376›Full record

Trial reportScientific reports2016

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.

Jack Godsell, Ina Rudloff, Rangi Kandane-Rathnayake, Alberta Hoi, Marcel F Nold, Eric F Morand, James Harris

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03583853 (Autophagy Genes and Interleukin-10 in Systemic Lupus Erythematosus Patients), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03583853 unknown statusnot on this mapstarted 2019, after this paper: background citation

Autophagy Genes and Interleukin-10 in Systemic Lupus Erythematosus Patients

TypeobservationalSponsorAssiut UniversityRan2019 to 2020Enrolled100ConditionsSystemic Lupus ErythematosusArmsreal time PCR
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jack GodsellRheumatology Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &Health Sciences, Monash University, Clayton, Victoria, Australia.
Ina RudloffRitchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Rangi Kandane-RathnayakeRheumatology Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &Health Sciences, Monash University, Clayton, Victoria, Australia.
Alberta HoiRheumatology Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &Health Sciences, Monash University, Clayton, Victoria, Australia.
Marcel F NoldRitchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Eric F MorandRheumatology Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &Health Sciences, Monash University, Clayton, Victoria, Australia.
James HarrisRheumatology Group, Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &Health Sciences, Monash University, Clayton, Victoria, Australia.
Monash Health · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the development of autoantibodies to nuclear antigens and inflammatory responses mediated by multiple cytokines. Although previous studies have determined clinical associations between SLE and the anti-inflammatory cytokines IL-10 and IL-37, their role in the disease, or their potential as biomarkers, remains unclear. We examined serum levels of IL-10 and IL-37 in a large cohort of SLE patients, with detailed longitudinal clinical data. We demonstrate a statistically significant association of serum IL-10 with disease activity, with higher levels in active compared to inactive disease. High first visit IL-10 was predictive of high subsequent disease activity; patients with IL-10 in highest quartile at first visit were 3.6 times more likely to have active disease in subsequent visits. Serum IL-37 was also higher in SLE patients compared to control, and was strongly associated with Asian ethnicity. However, IL-37 was not statistically significantly associated with disease activity. IL-37 was significantly reduced in patients with organ damage but this association was attenuated in multivariable analysis. The data suggest that IL-10, but not IL-37, may have potential as a biomarker predictive for disease activity in SLE.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersFemaleHumansInterleukin-1Interleukin-10Lupus Erythematosus, SystemicMaleMiddle AgedBiomarkersIL10 protein, humanIL37 protein, humanInterleukin-1Interleukin-10

Identifiers

PMID27708376
PMCPMC5052569
OpenAlexW2529347414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.